Lung Cancer Clinical Trials & Research at St. Joseph Health Medical Group
The two main types of lung cancer are non-small cell lung cancer and small
cell lung cancer. The types are based on the way the cells look under
a microscope. Non-small cell lung cancer is much more common than small
cell lung cancer. Tobacco smoking is the most common cause of lung cancer.
St. Joseph Health Medical Group is currently enrolling patients for the
following lung cancer clinical trials:
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Non-Small Cell Lung Cancer
Phase 2 Platform Study in Patients with advanced non-small lung cancer
who progressed on First Line Osimertinib therapy (ORCHARD)
Treatment agent: Osimertinib
PI:
Ian Anderson, MD
Study Coordinator: Tracy
Resources and Links:
clinicaltrials.gov NCT No: NCT03944772
Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib
(SAVANNAH)
Treatment agent: Osimertinib + Savolitinib
PI:
Ian Anderson, MD
Study Coordinator: Tracy
Resources and Links:
clinicaltrials.gov NCT No: NCT03778229
Tepotinib Phase II in Non-small cell lung cancer (NSCLC) Haboring MET Alterations (VISION)
Treatment: Tepotinib
PI:
Ian Anderson, MD
Study Coordinator: Tracy
Resources and Links:
clinicaltrials.gov NCT No: NCT02864992
A Phase 2 Trial of Pembrolizumab (MK-3475) in Combination with Platinum
Doublet Chemotherapy and Radiotherapy for Participants with Unresectable,
Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) (KEYNOTE-799)
Treatment agent: Platinum doublet chemo + radiotherapy + pembrolizumab
PI:
Ian Anderson, MD
Study Coordinator: Tracy Foster //
Tracy.Foster@stjoe.org // (707) 521-3836
Resources and Links:
clinicaltrials.gov NCT No: NCT03631784
Small Cell Lung Cancer
Study of Durvalumab + Tremelimuab, Durvalumab, and Placebo in Limited Stage
Small- Cell Lung Cancer in Patients who Have Not progressed following
concurrent chemoradiation therapy (ADRIATIC)
Treatment: Durvalumab + Tremelimuab, Durvalumab, and Placebo
PI:
Ian Anderson, MD
Study Coordinator: Tracy
Resources and Links:
clinicaltrials.gov NCT No: NCT03703297
Seer-020201 (Pulmonary Nodules)
Treatment: Durvalumab + Tremelimuab, Durvalumab, and Placebo
PI:
Manasa Vulchi, MD
Study Coordinator: Melissa
NCT – NA
A Study of Repotrectinib( TPX-005) in Patients with Advanced Solid Tumors
Harboring ALK, ROS1, or NTRK1-3 Rearrangments( TRIDENT-1)
Treatment: Oral repotrectinib
PI:
Ian Anderson, MD
Study Coordinator: Tracy
Resources and Links:
clinicaltrials.gov NCT No: NCT03093116